# Perceive Biotherapeutics

> Perceive Biotherapeutics is a privately held, clinical-stage biotechnology company developing ophthalmic gene therapies based on protective retinal biology. Its lead candidate, VOY-101, is being studied for geographic atrophy secondary to dry age-related macular degeneration. A separate spinout, Perceive Pharma, develops small molecule neuroprotective therapies.

- **Headquarters:** South San Francisco, United States
- **Founders:** Donald J. Zack (Scientific co-founder; scientific advisory board co-chair), Derek S. Welsbie (Scientific co-founder; scientific advisory board co-chair), Gregory S. Hageman (Scientific co-founder; Chief Science Officer)
- **Products:** VOY-101, OASIS
- **Notable:** Closed a USD 78 million Series B in January 2023., Advanced VOY-101 into human ophthalmology studies; first registered study lists a November 2022 start., Phase 1 safety findings were presented at ASRS 2025 and updated at ARVO 2026.

## Products & services

- **VOY-101** — Investigational intravitreal gene therapy intended to augment protective complement factor H biology in geographic atrophy secondary to non-neovascular AMD; studied in Phase 1/2a JOURNEY. Not an approved medicine.
- **OASIS** — Observational long-term safety extension for participants previously treated with VOY-101; a research study, not a commercial service.

## Achievements

- Closed a USD 78 million Series B in January 2023.
- Advanced VOY-101 into human ophthalmology studies; first registered study lists a November 2022 start.
- Phase 1 safety findings were presented at ASRS 2025 and updated at ARVO 2026.
- JOURNEY has progressed to its Phase 2 component and was active, not recruiting in its August 2026 update.

## Latest updates

- **2026-08** — JOURNEY registry updated August 17: active, not recruiting; estimated enrollment 60, primary completion October 2027, study completion June 2028.
- **2026-06** — OASIS long-term follow-up study first posted June 22; estimated enrollment 88, enrolling by invitation.
- **2026-05** — ARVO Phase 1 update described 24 treated patients, sustained transgene expression and early safety findings; efficacy remains to be established.
- **2025-02** — Perceive Pharma announced a separate USD 15 million Series A to develop small molecule neuroprotection.

## Links

- Website: https://www.perceivebio.com/
- LinkedIn: https://www.linkedin.com/company/perceive-bio

---

Profile page: https://yespress.io/perceive-biotherapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-10-01